PET/CT targeting IL-13Rα2 may be useful not only for the diagnosis of pancreatic cancer but also evaluating the expression level of IL-13Rα2 and predicting the efficacy of therapy targeting IL-13Rα2. This evidence concerns the gene IL13RA2 and familial pancreatic carcinoma.